Summary Workshop Report: Facilitating Oral Product Development and Reducing Regulatory Burden Through Novel Approaches to Assess Bioavailability/Bioequivalence
Journal Title: The AAPS Journal - Year 2012, Vol 14, Issue 3
Abstract
This summary workshop report highlights presentations and over-arching themes from an October 2011 workshop. Discussions focused on best practices in the application of biopharmaceutics in oral drug product development and evolving bioequivalence approaches. Best practices leverage biopharmaceutic data and other drug, formulation, and patient/disease data to identify drug development challenges in yielding a successfully performing product. Quality by design and product developability paradigms were discussed. Development tools include early development strategies to identify critical absorption factors and oral absorption modeling. An ongoing theme was the desire to comprehensively and systematically assess risk of product failure via the quality target product profile and root cause and risk analysis. However, a parallel need is reduced timelines and fewer resources. Several presentations discussed applying Biopharmaceutics Classification System (BCS) and in vitro–in vivo correlations in development and in post-development and discussed both resource savings and best scientific practices. The workshop also focused on evolving bioequivalence approaches, with emphasis on highly variable products (HVDP), as well as specialized modified-release products. In USA, two bioequivalence approaches for HVDP are the reference-scaled average bioequivalence approach and the two-stage group-sequential design. An adaptive sequential design approach is also acceptable in Canada. In European Union, two approaches for HVDP are a two-stage design and an approach to widen Cmax acceptance limits. For some specialized modified-release products, FDA now requests partial area under the curve. Rationale and limitations of such metrics were discussed (e.g., zolpidem and methylphenidate). A common theme was the benefit of the scientific and regulatory community developing, validating, and harmonizing newer bioequivalence methodologies (e.g., BCS-based waivers and HVDP trial designs).
Authors and Affiliations
James E. Polli, Jack A. Cook, Barbara M. Davit, Paul A. Dickinson, Domenick Argenti, Nancy Barbour, Alfredo García-Arieta, Jean-Marie Geoffroy, Kerry Hartauer, Shoufeng Li, Amitava Mitra, Francis X. Muller, Vivek Purohit, Manuel Sanchez-Felix, John W. Skoug, Kin Tang
Keywords
Related Articles
- EP ID EP681252
- DOI 10.1208/s12248-012-9376-z
- Views 60
- Downloads 0
Linking human and veterinary health: Trends, directions and initiatives
The objective of this brief article is to provide an overview of some of the important harmonization efforts that are currently under way within the animal health community. Topics include: scientific networks and interd...
Utilization of Gene Expression Signature for Quality Control of Traditional Chinese Medicine Formula Si-Wu-Tang
The online version of this article (doi:10.1208/s12248-013-9491-5) contains supplementary material, which is available to authorized users.
Ligand-Binding Assay Development: What Do You Want to Measure Versus What You Are Measuring?
The analysis of biotherapeutics by ligand-binding assay (LBA) is associated with some unique challenges that are unlike those commonly encountered in chromatographic methods for chemically based small molecule drugs. Whi...
Pharma Success in Product Development—Does Biotechnology Change the Paradigm in Product Development and Attrition
The biotechnology segment of the overall biopharma industry has existed for only about 40–45 years, as a driver of new product development. This driving force was initiated with the FDA approval of recomb...
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
The monoclonal antibody market continues to witness an impressive rate of growth and has become the leading source of expansion in the biologic segment within the pharmaceutical industry. Currently marketed monoclonal an...